ClinVar Miner

Submissions for variant NM_000518.5(HBB):c.61G>A (p.Val21Met)

gnomAD frequency: 0.00001  dbSNP: rs35890959
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000759801 SCV000889375 pathogenic not provided 2018-06-22 criteria provided, single submitter clinical testing The HBB c.61G>A (p.Val21Met) variant, also known as Hb Olympia has been reported in individuals presenting with erythrocytosis (PMIDs: 35052427 (2022), 23859443 (2013), and 2599884 (1989)). In addition, this variant has been reported to have increased oxygen affinity and is mildly unstable (PMIDs: 31553106 (2020) and 2599884 (1989)). Based on the available information, this variant is classified as pathogenic.
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000759801 SCV001474509 pathogenic not provided 2020-03-04 criteria provided, single submitter clinical testing The Hb Olympia variant (HBB: c.61G>A; p.Val21Met, also known as Val20Met when numbered from the mature protein, rs35890959) is reported in the literature in multiple individuals affected with erythrocytosis (Bento 2013, Gonzalez Fernandez 2009, Percy 2009, Stamatoyannopoulos 1973, Wajcman 2005, HbVar database and references therein). This variant has been observed to segregate with erythrocytosis in a family in a pattern consistent with autosomal dominant inheritance (Stamatoyannopoulos 1973). Further, while heterozygous individuals with this variant are reported with mild erythrocytosis, those carrying both Hb Olympia and a beta-thalassemia allele are reported to exhibit more severe symptoms (Wajcman 2005). The Hb Olympia variant is found on a single chromosome in the Genome Aggregation Database (1/251260 alleles), indicating it is not a common polymorphism. The valine at codon 21 is highly conserved, and functional studies indicate increased oxygen affinity of the variant protein (Stamatoyannopoulos 1973). Based on available information, this variant is considered to be pathogenic. References: HbVar link to Hb Olympia: http://globin.bx.psu.edu/cgi-bin/hbvar/query_vars3?mode=output&display_format=page&i=257 Bento C et al. Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?). Eur J Haematol. 2013 Oct;91(4):361-8. Gonzalez Fernandez FA et al. Haemoglobinopathies with high oxygen affinity. Experience of Erythropathology Cooperative Spanish Group. Ann Hematol. 2009 Mar;88(3):235-8. Percy MJ et al. Identification of high oxygen affinity hemoglobin variants in the investigation of patients with erythrocytosis. Haematologica. 2009 Sep;94(9):1321-2. Stamatoyannopoulos G et al. Hemoglobin olympia ( 20 valine leads to methionine): an electrophoretically silent variant associated with high oxygen affinity and erythrocytosis. J Clin Invest. 1973 Feb;52(2):342-9. Wajcman H and Galacteros F. Hemoglobins with high oxygen affinity leading to erythrocytosis. New variants and new concepts. Hemoglobin. 2005;29(2):91-106.
Fulgent Genetics, Fulgent Genetics RCV002496379 SCV002808190 pathogenic Dominant beta-thalassemia; Heinz body anemia; Hb SS disease; alpha Thalassemia; Malaria, susceptibility to; Methemoglobinemia, beta-globin type; Erythrocytosis, familial, 6; Hereditary persistence of fetal hemoglobin; Beta-thalassemia HBB/LCRB 2022-01-11 criteria provided, single submitter clinical testing
OMIM RCV000016533 SCV000036801 other HEMOGLOBIN OLYMPIA 2017-12-12 no assertion criteria provided literature only
OMIM RCV000641556 SCV000763198 pathogenic Erythrocytosis, familial, 6 1987-11-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.